Soluble Ferric Pyrophosphate: Completed Phase III enrollment

Rockwell Medical said it completed enrollment in the double-blind, placebo-controlled Phase III CRUISE-2 trial evaluating 11 µg/dL SFP delivered via dialysate 3-4 times per week for up to 18 months in...